跳至主導覽
跳至搜尋
跳過主要內容
國立陽明交通大學研發優勢分析平台 首頁
English
中文
首頁
人員
單位
研究成果
計畫
獎項
活動
貴重儀器
影響
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
陳 儀聰
助理教授
生命科學系暨基因體科學研究所
https://orcid.org/0000-0002-3891-5172
電話
02-2826-7000 ext.66249
電子郵件
yeitsungchen
nycu.edu
tw
網站
https://dls.nycu.edu.tw/faculty/faculty-member/ytchen.html
h-index
h10-index
h5-index
2027
引文
20
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
807
引文
12
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
35
引文
4
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2002
2025
每年研究成果
概覽
指紋
網路
研究成果
(38)
類似的個人檔案
(1)
指紋
查看啟用 Yei-Tsung Chen 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Keyphrases
Prostate Cancer
96%
MicroRNA
82%
Androgen Receptor
69%
Heart Failure
59%
Genetic Analysis
57%
Testicular Orphan nuclear Receptor 4
48%
Circulating microRNA
43%
Androgen Deprivation Therapy
40%
IKBKAP
38%
Heart Failure with Preserved Ejection Fraction (HFpEF)
37%
Familial Dysautonomia
33%
Genetic Variants
32%
Cerebellum
32%
MicroRNA Profile
32%
Cardiac Cells
30%
Spermatogenesis
27%
Natriuretic Peptide Receptor 3
27%
Cerebellar Development
27%
Orphan nuclear Receptor
27%
Expression Analysis
27%
Prostate Cancer Recurrence
27%
DENND2D
27%
Neurohormonal
21%
ELP1
20%
RNA Splicing
19%
Patients with Prostate Cancer
19%
Cancer-specific Survival
18%
Cancer Progression
18%
Testicular Receptor 4
18%
Further Analysis
18%
Overall Survival
18%
Apoptosis
17%
N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)
17%
Androgens
16%
Cardiovascular Disease
15%
Prostate Cancer Progression
15%
Elongator
15%
Embryonic Lethality
15%
Left Ventricle
15%
Phosphoinositide 3-kinase (PI3K)
15%
Single nucleotide Polymorphism
15%
Progression-free Survival
15%
Motor Coordination
14%
Cytoarchitecture
14%
Granule Cell
14%
High-level Expression
14%
Meiotic Division
13%
ARA70
13%
MicroRNA-145
13%
Myxomatous Mitral Valve
13%
Biochemistry, Genetics and Molecular Biology
MicroRNA
100%
Single-Nucleotide Polymorphism
51%
Genetics
46%
Allele
45%
Natriuretic Peptide
41%
Androgen Receptor
41%
Biochemical Recurrence Free Survival
37%
Genetic Divergence
34%
Progression Free Survival
32%
Overall Survival
32%
Carcinogenesis
32%
Gene Expression
32%
IKBKAP
27%
Peptide Receptor
27%
Cancer Specific Survival
27%
Orphan Nuclear Receptor
27%
Genome-Wide Analysis of Gene Expression
27%
Immunomodulation
27%
ALDH1A2
27%
Heart Ejection Fraction
22%
Cancer Cell
17%
N-Terminus
17%
Transactivation
15%
Heart Left Ventricle Ejection Fraction
15%
Messenger RNA
15%
Phosphoinositide 3-Kinase
14%
DNA Mismatch Repair
13%
MSH2
13%
Ankyrin
13%
Ankyrin Repeat
13%
Mir-143
13%
Gene Repression
13%
ATP8B1
13%
Insulin Resistance
13%
LNCaP
13%
TNFRSF13B
13%
Synapsin I
13%
Ubiquitin
13%
Tumor Marker
13%
Estradiol
13%
Prophase
13%
Protease
13%
Spermatogenesis
13%
Protein Kinase B
13%
Programmed Cell Death
13%
Expression Analysis
13%
RNA Splicing
12%
Wild Type
10%
Phospholipid
9%
Globin
9%
Medicine and Dentistry
microRNA
73%
Androgen Receptor
55%
Congestive Heart Failure
48%
Prostate Cancer
42%
Orphan Nuclear Receptor
41%
Circulating microRNA
29%
Spermiogenesis
27%
Biological Marker
23%
Diagnosis
20%
Androgen
16%
Heart Left Ventricle Ejection Fraction
15%
Cancer Cell
15%
Phosphoinositide 3-Kinase
13%
Motor Coordination
13%
Programmed Cell Death
13%
Receptor Expression
13%
Maternal Behavior
13%
Heart Failure with Reduced Ejection Fraction
13%
Medicine
13%
Genetic Analysis
13%
DNA Mismatch Repair
13%
Ejection Fraction
13%
Bladder Cancer
13%
Cerebellum
13%
Mitral Valve Prolapse
13%
Growth Retardation
13%
Transactivation
13%
Left Ventricle
13%
Granule Cell
13%
Helix
13%
Diethylstilbestrol
13%
Prophase
13%
Division
13%
Protein Kinase B
13%
Cancer Recurrence
13%
Diseases
11%
Testes
9%
In Vitro
8%
Cell Nucleus Receptor
7%
Biochemical Recurrence
6%
Cardiovascular System
6%
Partial Androgen Insensitivity Syndrome
6%
Gene Expression
6%
Cell Proliferation
6%
Cell Signaling Pathway
6%
DNA Repair
5%
Single Nucleotide Polymorphism
5%
